Clinical trial · Interventional
Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy
Phase II Trial To Evaluate The Potential For Helical Tomotherapy IMRT To Improve Bladder Cancer Chemoradiation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): More advanced treatments superceded study design
Summary
Brief summary (as posted)
While the gold standard of treatment in invasive bladder cancer is surgical removal of the bladder, it is well accepted that a reasonable alternative is an organ preserving approach. Bladder preservation can be achieved in patients with radiotherapy alone or together with concurrent chemotherapy. This clinical trial will assess the potential of intensity modulated radiation therapy (IMRT) delivered using helical tomotherapy to reduce radiation-induced gastrointestinal toxicity and increase the accuracy of bladder cancer irradiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Helical tomotherapy IMRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Helical tomotherapy IMRT
- description
- Helical tomotherapy IMRT
- interventionNames
- Radiation: Helical tomotherapy IMRT
Primary outcomes (1)
- measure
- Acute GI toxicity
Secondary outcomes (1)
- measure
- Dosimetric evaluation of bowel and pelvic marrow radiation dose, Bladder time organ motion studies, Patterns of recurrence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. A pathological diagnosis of pure or predominantly transitional cell bladder carcinoma 2. Adequate Hematology and biochemistry parameters 3. Invasive or treatment refractory non-invasive transitional cell bladder carcinoma OR operable patients who prefer bladder preservation OR inoperable patients. 4. No metastases on CT scan of chest Exclusion Criteria: 1. Patient with contraindication to radical radiotherapy including inflammatory bowel disease or significant irritative bladder symptoms 2. Contraindication to internal iliac arterial catheterization 3. Prior pelvic radiotherapy for other malignancies 4. Prior cytotoxic chemotherapy excepting intravesical agents
References
Publications (0)
Data not yet available